Design and Rationale of the Non-Interventional, Edoxaban Treatment in routiNe Clinical prActice in Patients With Venous ThromboEmbolism in Europe (ETNA-VTE-Europe) Study

Thrombosis Journal - United Kingdom
doi 10.1186/s12959-018-0163-7
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Edoxaban for Treatment of Venous Thromboembolism in Patients With Cancer

Thrombosis and Haemostasis
Hematology
2015English

Incidence Rates, Clinical Profile, and Outcomes of Patients With Venous Thromboembolism. The Worcester VTE Study

Journal of Thrombosis and Thrombolysis
Cardiovascular MedicineHematologyCardiology
2009English

Costs of Venous Thromboembolism (Vte) Among Hospitalized Patients in China

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

2019 International Clinical Practice Guidelines for the Treatment and Prophylaxis of Venous Thromboembolism in Patients With Cancer

The Lancet Oncology
Oncology
2019English

Edoxaban in Venous Thromboembolism and Stroke Prevention: An Appraisal

Vascular Health and Risk Management
2016English

Application of Treat-To-Target Principles in Patients With Early Rheumatoid Arthritis in Routine Clinical Practice in Central-Eastern Europe

International Journal of Clinical Rheumatology
Rheumatology
2018English

The Cost-Effectiveness of Dabigatran Etexilate Compared With Edoxaban in the Treatment of Acute Venous Thromboembolism in the Uk

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Prevention and Treatment of Venous Thromboembolism in Patients With Cancer

Therapeutic Advances in Hematology
Hematology
2011English

Prevention and Treatment of Venous Thromboembolism in Patients With Cancer

Canadian Pharmacists Journal
Pharmaceutical SciencePharmacy
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy